Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Tuberculosis infection risk, preventive therapy care cascade and incidence of tuberculosis disease in healthcare workers at Maputo Central Hospital.

Graves SK, Augusto O, Viegas SO, Lederer P, David C, Lee K, Hassane A, Cossa A, Amade S, Peleve S, Zindoga P, Massawo L, Torriani FJ, Nunes EA.

BMC Infect Dis. 2019 Apr 25;19(1):346. doi: 10.1186/s12879-019-3966-7.

2.

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus.

Cachay ER, Mena A, Morano L, Benitez L, Maida I, Ballard C, Hill L, Torriani F, Castro A, Dore E, Castro S, de Mendoza Fernández C, Soriano V, Mathews WC; HCV-TREN Cohort.

Open Forum Infect Dis. 2019 Feb 11;6(3):ofz070. doi: 10.1093/ofid/ofz070. eCollection 2019 Mar.

3.

Predictors of Missed Hepatitis C Intake Appointments and Failure to Establish Hepatitis C Care Among Patients Living With HIV.

Cachay ER, Hill L, Torriani F, Ballard C, Grelotti D, Aquino A, Christopher Mathews W.

Open Forum Infect Dis. 2018 Jul 31;5(7):ofy173. doi: 10.1093/ofid/ofy173. eCollection 2018 Jul.

4.

Transforming acne care by pediatricians: An interventional cohort study.

Borok J, Udkoff J, Vaida F, Murphy J, Torriani F, Waldman A, Ahluwalia J, Eichenfield LF.

J Am Acad Dermatol. 2018 Nov;79(5):966-968. doi: 10.1016/j.jaad.2018.04.055. Epub 2018 May 10. No abstract available.

5.

Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment.

Cachay ER, Ballard C, Colwell B, Torriani F, Hicks C, Mathews WC.

AIDS Res Ther. 2017 Sep 20;14(1):56. doi: 10.1186/s12981-017-0182-7.

6.

Tumour control in ion beam radiotherapy with different ions in the presence of hypoxia: an oxygen enhancement ratio model based on the microdosimetric kinetic model.

Strigari L, Torriani F, Manganaro L, Inaniwa T, Dalmasso F, Cirio R, Attili A.

Phys Med Biol. 2018 Mar 16;63(6):065012. doi: 10.1088/1361-6560/aa89ae.

PMID:
28862152
7.

Correction: Longitudinal Metagenomic Analysis of Hospital Air Identifies Clinically Relevant Microbes.

King P, Pham LK, Waltz S, Sphar D, Yamamoto RT, Conrad D, Taplitz R, Torriani F, Forsyth RA.

PLoS One. 2016 Dec 28;11(12):e0169376. doi: 10.1371/journal.pone.0169376. eCollection 2016.

8.

Standardized Infection Ratio for Surgical Site Infection after Colon Surgery: Discord in Models Measuring Healthcare Quality.

Chinn R, Lempp JM, Huang SS, Murthy R, Torriani FJ, Daley J, Dekker E, Goss-Bottorff B, Kaler W, Meyer K, Myers F, Nichols A, Kathleen Quan, Birnbaum D.

Infect Control Hosp Epidemiol. 2016 Nov;37(11):1378-1382. Epub 2016 Aug 30.

9.

Longitudinal Metagenomic Analysis of Hospital Air Identifies Clinically Relevant Microbes.

King P, Pham LK, Waltz S, Sphar D, Yamamoto RT, Conrad D, Taplitz R, Torriani F, Forsyth RA.

PLoS One. 2016 Aug 2;11(8):e0160124. doi: 10.1371/journal.pone.0160124. eCollection 2016. Erratum in: PLoS One. 2016 Dec 28;11(12 ):e0169376.

10.

Bacterial and viral co-infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013-14.

Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J 4th, Mangino JE, Weber DM, Hebert CL, Marzec NS, Barron MA, Chaparro-Rojas F, Restrepo A, Hemmige V, Prasidthrathsint K, Cobb S, Herwaldt L, Raabe V, Cannavino CR, Hines AG, Bares SH, Antiporta PB, Scardina T, Patel U, Reid G, Mohazabnia P, Kachhdiya S, Le BM, Park CJ, Ostrowsky B, Robicsek A, Smith BA, Schied J, Bhatti MM, Mayer S, Sikka M, Murphy-Aguilu I, Patwari P, Abeles SR, Torriani FJ, Abbas Z, Toya S, Doktor K, Chakrabarti A, Doblecki-Lewis S, Looney DJ, David MZ.

J Clin Virol. 2016 Jul;80:12-9. doi: 10.1016/j.jcv.2016.04.008. Epub 2016 Apr 14.

PMID:
27130980
11.

The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.

Cachay ER, Wyles D, Hill L, Ballard C, Torriani F, Colwell B, Kuo A, Schooley R, Mathews CW.

Open Forum Infect Dis. 2015 Nov 12;2(4):ofv168. doi: 10.1093/ofid/ofv168. eCollection 2015 Dec.

12.

Severe Influenza in 33 US Hospitals, 2013-2014: Complications and Risk Factors for Death in 507 Patients.

Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell J, Mangino JE, Weber DM, Hebert CL, Marzec NS, Barron MA, Chaparro-Rojas F, Restrepo A, Hemmige V, Prasidthrathsint K, Cobb S, Herwaldt L, Raabe V, Cannavino CR, Hines AG, Bares SH, Antiporta PB, Scardina T, Patel U, Reid G, Mohazabnia P, Kachhdiya S, Le BM, Park CJ, Ostrowsky B, Robicsek A, Smith BA, Schied J, Bhatti MM, Mayer S, Sikka M, Murphy-Aguilu I, Patwari P, Abeles SR, Torriani FJ, Abbas Z, Toya S, Doktor K, Chakrabarti A, Doblecki-Lewis S, Looney DJ, David MZ.

Infect Control Hosp Epidemiol. 2015 Nov;36(11):1251-60. doi: 10.1017/ice.2015.170. Epub 2015 Jul 30.

PMID:
26224364
13.

Acute HIV infection presenting as fulminant meningoencephalitis with massive CSF viral replication.

Andrade RM, Torriani FJ, Ellis RJ.

Neurol Clin Pract. 2014 Jun;4(3):256-259.

14.

The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care.

Cachay ER, Hill L, Wyles D, Colwell B, Ballard C, Torriani F, Mathews WC.

PLoS One. 2014 Jul 18;9(7):e102883. doi: 10.1371/journal.pone.0102883. eCollection 2014.

15.

Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation.

Hulgan T, Stein JH, Cotter BR, Murdock DG, Ritchie MD, Dube MP, Gerschenson M, Haas DW, Torriani FJ; Aids Clinical Trials Group A5152s And Dacs 252 Study Teams.

AIDS Res Hum Retroviruses. 2013 Oct;29(10):1293-9. doi: 10.1089/aid.2013.0079. Epub 2013 Aug 14.

16.

High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.

Cachay ER, Wyles DL, Torriani FJ, Ballard C, Colwell B, Lin JC, Hill L, Mathews WC.

AIDS. 2013 Nov 28;27(18):2893-7. doi: 10.1097/01.aids.0000432466.15885.14.

PMID:
23842130
17.

Genome of the pathogen Porphyromonas gingivalis recovered from a biofilm in a hospital sink using a high-throughput single-cell genomics platform.

McLean JS, Lombardo MJ, Ziegler MG, Novotny M, Yee-Greenbaum J, Badger JH, Tesler G, Nurk S, Lesin V, Brami D, Hall AP, Edlund A, Allen LZ, Durkin S, Reed S, Torriani F, Nealson KH, Pevzner PA, Friedman R, Venter JC, Lasken RS.

Genome Res. 2013 May;23(5):867-77. doi: 10.1101/gr.150433.112. Epub 2013 Apr 5.

18.

Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model.

Cachay ER, Hill L, Ballard C, Colwell B, Torriani F, Wyles D, Mathews WC.

AIDS Res Ther. 2013 Mar 28;10(1):9. doi: 10.1186/1742-6405-10-9.

19.

Discord among performance measures for central line-associated bloodstream infection.

Tehrani DM, Russell D, Brown J, Boynton-Delahanty K, Quan K, Gibbs L, Braddock G, Zaroda T, Koopman M, Thompson D, Nichols A, Cui E, Liu C, Cohen S, Rubin Z, Pegues D, Torriani F, Datta R, Huang SS.

Infect Control Hosp Epidemiol. 2013 Feb;34(2):176-83. doi: 10.1086/669090. Epub 2012 Dec 14.

PMID:
23295564
20.

The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV.

Opravil M, Rodriguez-Torres M, Rockstroh J, Snoeck E, Chung RT, Tietz A, Torriani FJ.

HIV Clin Trials. 2012 Jan-Feb;13(1):33-45. doi: 10.1310/hct1301-033.

PMID:
22306586
21.

Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment.

Cachay ER, Wyles DL, Goicoechea M, Torriani FJ, Ballard C, Colwell B, Gish RG, Mathews WC.

AIDS Res Ther. 2011 Aug 10;8:29. doi: 10.1186/1742-6405-8-29.

22.

Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis.

Bhattacharya D, Umbleja T, Carrat F, Chung RT, Peters MG, Torriani F, Andersen J, Currier JS.

J Acquir Immune Defic Syndr. 2010 Oct;55(2):170-5. doi: 10.1097/QAI.0b013e3181e36420.

23.

Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin.

Rodriguez-Torres M, Torriani F, Rockstroh J, Depamphilis J, Carosi G, Dieterich DT.

HIV Clin Trials. 2010 Jan-Feb;11(1):1-10. doi: 10.1310/hct1101-1.

PMID:
20400406
24.

Lessons learned from the institution of the Surgical Care Improvement Project at a teaching medical center.

Potenza B, Deligencia M, Estigoy B, Faraday E, Snyder A, Angle N, Schwartz A, Chang L, Hackett J, Minokadeh A, Madani M, MacAulay K, Ramamoorthy S, Blaner L, James C, Bansal V, Torriani F, Coimbra R.

Am J Surg. 2009 Dec;198(6):881-8. doi: 10.1016/j.amjsurg.2009.08.015.

PMID:
19969146
25.

Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.

Stein JH, Komarow L, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Parker RA, Torriani FJ; ACTG 5152s Study Team.

J Clin Lipidol. 2008 Dec;2(6):464-471.

26.

Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.

Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein JH; SABAR Study Team.

AIDS. 2010 Mar 27;24(6):885-90. doi: 10.1097/QAD.0b013e3283352ed5.

PMID:
19952712
27.

Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl.

Maragakis LL, Chaiwarith R, Srinivasan A, Torriani FJ, Avdic E, Lee A, Ross TR, Carroll KC, Perl TM.

Emerg Infect Dis. 2009 Jan;15(1):12-8. doi: 10.3201/eid1501.081054.

28.

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH; ACTG 5152s Study Team.

J Am Coll Cardiol. 2008 Aug 12;52(7):569-76. doi: 10.1016/j.jacc.2008.04.049.

29.

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.

Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT.

J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):36-49.

PMID:
18156990
30.

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.

Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, Bellomi F, Filice G, Antonelli G.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):369-76.

31.

Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.

Dore GJ, Torriani FJ, Rodriguez-Torres M, Bräu N, Sulkowski M, Lamoglia RS, Tural C, Clumeck N, Nelson MR, Mendes-Correa MC, Godofsky EW, Dieterich DT, Yetzer E, Lissen E, Cooper DA.

AIDS. 2007 Jul 31;21(12):1555-9.

PMID:
17630550
32.

Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults.

Currier JS, Kendall MA, Henry WK, Alston-Smith B, Torriani FJ, Tebas P, Li Y, Hodis HN.

AIDS. 2007 May 31;21(9):1137-45.

PMID:
17502724
33.

Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?

Rodríguez-Torres M, Gonzalez-Garcia J, Bräu N, Solá R, Moreno S, Rockstroh J, Smaill F, Mendes-Correa MC, DePamphilis J, Torriani FJ; APRICOT Investigators.

J Med Virol. 2007 Jun;79(6):694-700.

PMID:
17457912
34.

Community-associated methicillin-resistant Staphylococcus aureus in the patient with HIV infection.

Thompson K, Torriani F.

Curr HIV/AIDS Rep. 2006 Sep;3(3):107-12. Review.

PMID:
16970836
35.

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, Torres MR, Green J, Patel K.

J Clin Virol. 2006 Aug;36(4):283-91. Epub 2006 Jun 9.

PMID:
16765638
36.

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators.

Hepatology. 2006 Jun;43(6):1317-25.

PMID:
16729309
37.

Response to: 'carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients'.

Currier JS, Kendall MA, Henry WK, Torriani FJ, Hodis HN; ACTG 5078 Study Team.

AIDS. 2006 Jan 9;20(2):311. No abstract available.

PMID:
16511437
38.

Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis.

Schrier RD, Song MK, Smith IL, Karavellas MP, Bartsch DU, Torriani FJ, Garcia CR, Freeman WR.

Retina. 2006 Feb;26(2):165-9.

PMID:
16467672
39.

A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team.

AIDS Res Hum Retroviruses. 2005 Sep;21(9):757-67.

PMID:
16218799
40.

The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy.

Wohl DA, Kendall MA, Owens S, Holland G, Nokta M, Spector SA, Schrier R, Fiscus S, Davis M, Jacobson MA, Currier JS, Squires K, Alston-Smith B, Andersen J, Freeman WR, Higgins M, Torriani FJ; ACTG 379 Study Team.

HIV Clin Trials. 2005 May-Jun;6(3):136-46.

PMID:
16192248
41.

Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.

Rodriguez-Torres M, Torriani FJ, Soriano V, Borucki MJ, Lissen E, Sulkowski M, Dieterich D, Wang K, Gries JM, Hoggard PG, Back D.

Antimicrob Agents Chemother. 2005 Oct;49(10):3997-4008.

42.

Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults.

Mathews WC, Caperna JC, Barber RE, Torriani FJ, Miller LG, May S, McCutchan JA.

J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):155-60.

PMID:
16186732
43.

Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.

Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, Schouten J, Mickelberg K, Li Y, Hodis HN; AACTG 5078 Study Team.

AIDS. 2005 Jun 10;19(9):927-33.

44.

Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections.

Torriani FJ, Chung RT.

ACP J Club. 2005 Jan-Feb;142(1):A12; author reply A13. No abstract available.

PMID:
15656540
45.
46.

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.

Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D.

AIDS. 2004 Sep 3;18(13):F21-5.

PMID:
15316334
47.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group.

N Engl J Med. 2004 Jul 29;351(5):438-50.

48.
49.

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection.

Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, Perelson AS.

J Infect Dis. 2003 Nov 15;188(10):1498-507. Epub 2003 Nov 13.

PMID:
14624375
50.

Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis.

Song MK, Azen SP, Buley A, Torriani F, Cheng L, Chaidhawangul S, Ozerdem U, Scholz B, Freeman WR.

Am J Ophthalmol. 2003 Oct;136(4):696-702.

PMID:
14516810

Supplemental Content

Loading ...
Support Center